Beyond Headlines Into Insight
This new medication, approved by the US FDA in October 2023, combines 1,000 mg of acetaminophen and 300 mg of ibuprofen to address mild to severe pain in adults. The introduction of Combogesic IV offers healthcare providers in the US an innovative and non-opioid option for pain management. The American Society of Anesthesiology (ASA) emphasizes
Read More
Spectrum supports study teams by providing real-time predictions and control over trial timelines and costs, ensuring successful trials in today’s complex landscape. Clinical trials today are more intricate than ever. Late-phase studies now collect over 3.5 million data points, triple the amount from a decade ago, and must juggle an average of 26 endpoints, including
Read More
This key study explores the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics (PK) of delta-9-tetrahydrocannabinol (THC) and its active metabolites in Alzheimer’s disease (AD) patients. Titled ‘A study on CYP2C9 polymorphism, in Puerto Rican Alzheimer’s patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocannabinol,’ it is accessible at the European Society of Medicine website.
Read More
However, the eCOA/ePRO market has seen minimal innovation since the transition from paper-based forms to digital formats two decades ago, leaving a gap in meeting the escalating demand for improved patient reported outcomes driven by heightened regulatory requirements. Speaking on the pressing need for industry-wide transformation, Steve Rosenberg, CEO of eCOA/ePRO provider uMotif, he said:
Read More
However, the eCOA/ePRO market has seen minimal innovation since the transition from paper-based forms to digital formats two decades ago, leaving a gap in meeting the escalating demand for improved patient reported outcomes driven by heightened regulatory requirements. Speaking on the pressing need for industry-wide transformation, Steve Rosenberg, CEO of eCOA/ePRO provider uMotif, he said:
Read More
Promising to redefine the landscape with its latest solutions, the company hopes to take center stage, offering advancements in data management and patient engagement. Join us for an exclusive preview of how Qinesca is poised to win over the industry and why this unveiling is the must-see event of the conference. Product and Service Innovations:
Read More
John Romano, president, and co-founder, shares exclusive insights into how these innovations are set to tackle industry challenges and enhance patient outcomes. Can you share any new products or services your company is unveiling at this year’s DIA? The Gifthealth team continues to innovate and develop tools to improve the medication access journey for patients.
Read More
This was to discuss what they describe as the groundbreaking impact of their Sub-population Optimization & Modeling Solution (SOMS). This cutting-edge technology, he says, integrated with advanced artificial intelligence, is poised to transform the landscape of clinical trials. Here’s what you need to know about how SOMS is setting new standards in trial precision, rescue
Read More
Advarra is set to reveal solutions tailored to address current challenges in the pharmaceutical and healthcare industries. With the results from the 2023 Advarra Site Survey highlighting the burden of training and use of sponsor technology on sites, it is putting forward solutions such as single sign-on and integrated technology ecosystems to streamline study start-up
Read More
This innovative technology allows study teams to predict, optimize, and control trial timelines and costs in real-time, enabling iterative feasibility analysis and mid-study course correction. By automatically incorporating ongoing financial forecasting, Spectrum dynamically adjusts budgets based on real data, ensuring accurate modeling and efficient trial management. Product and Service Innovations: Can you share any new
Read More